

2020 年度

[受賞]

第 4 回国際がん研究シンポジウム Young Investigator Award (朴 将源)

第 27 回日本がんチーム医療研究会 優秀演題賞 (中島 千寿)

[論文・著書]

Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H, Nakamura M, Watanabe T, Matsumoto T, Kii T, Terazawa T, Makiyama A, Takano N, Yokota M, Okita Y, Matoba K, Hasegawa H, Tsuji A, Komatsu Y, Yoshino T, Yamazaki K, Mishima H, Oki E, Nagata N, Sakamoto J : Phase Ib/II Study of Biweekly TAS - 102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS study). *Oncologist* 25: e1855-e1863, 2020

Satake H, Ando K, Oki E, Shimokawa M, Makiyama A, Saeki H, Tsuji A, Mori M : Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer. *BMC Cancer* 20: 1116, 2020

Ogata M, Kotaka M, Ogata T, Hatachi Y, Yasui H, Kato T, Tsuji A, Satake H : Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. *PLoS One* 15:e0234314, 2020

Kito Y, Satake H, Taniguchi H, Yamada T, Horie Y, Esaki T, Denda T, Yasui H, Izawa N, Masuishi T, Moriwaki T, Mori K, Yamazaki K : Kito Y, Satake H, Taniguchi H, Yamada T, Horie Y, Esaki T, Denda T, Yasui H, Izawa N, Masuishi T, Moriwaki T, Mori K, Yamazaki K: Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer. *Cancer Chemother Pharmacol* 86:277-284, 2020

Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J : Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. *JAMA Oncol* 6:1571-1580, 2020

- Ooki A, Morita S, Tsuji A, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Ando M, Sakamoto J, Yamaguchi K : Disagreement between patient- and physician-reported outcomes on symptom adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. *Cancer Med* 9:9419-9430, 2020
- Terazawa T, Kato T, Goto M, Ohta K, Noura S, Satake H, Kagawa Y, Kawakami H, Hasegawa H, Yanagihara K, Shingai T, Nakata K, Kotaka M, Hiraki M, Konishi K, Nakae S, Sakai D, Kurokawa Y, Shimokawa T, Satoh T : Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naive Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGSG 1602. *Oncologist* 26:17-e47, 2021
- Ishibashi K, Aoyama T, Kotaka M, Satake H, Tsuji Y, Kataoka M, Nakamura M, Nagata N, Sakamoto J, Oba K, Mishima H : Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study). *Cancer Chemother Pharmacol*, Feb 8, 2021
- Shinozaki E, Makiyama A, Kagawa Y, Satake H, Tanizawa Y, Cai Z, Piao Y: Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database. *PLoS One* 16: e0246160, 2021
- Sai S, Toyoda M, Tobimatsu K, Satake H, Yasui H, Kimbara S, Koyama T, Fujishima Y, Imamura Y, Funakoshi Y, Kiyota N, Toyama H, Kodama Y, Minami H : Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial). *Cancer Chemother Pharmacol* 87: 65-71, 2021
- Kotaka M, Saito Y, Kato T, Satake H, Makiyama A, Tsuji Y, Shinozaki K, Fujiwara T, Mizushima T, Harihara Y, Nagata N, Kurihara N, Ando M, Kusakawa G, Sakai T, Uchida Y, Takamoto M, Kimoto S, Hyodo I : A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy. *Cancer Chemother Pharmacol* 86: 607-618, 2020
- Miyo M, Kato T, Yoshino T, Yamanaka T, Bando H, Satake H, Yamazaki K, Taniguchi H, Oki E, Kotaka M, Oba K, Miyata Y, Muro K, Komatsu Y, Baba H, Tsuji A : Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. *BMC Cancer* 20:687, 2020

- Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M : Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. *Cancer Chemother Pharmacol* 85:217-223, 2020
- Suzuki T, Sukawa Y, Imamura CK, Masuishi T, Satake H, Kumekawa Y, Funakoshi S, Kotaka M, Horie Y, Kawai S, Okuda H, Terazawa T, Kondoh C, Kato K, Yoshimura K, Ishikawa H, Hamamoto Y, Boku N, Takaishi H, Kanai T : A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). *Clin Colorectal Cancer* 19: 13-21, 2020
- Ooki A, Morita S, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K : Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. *Cancer Med* 9:1779-1789, 2020
- Nomura M, Oze I, Masuishi T, Yokota T, Satake H, Iwasawa S, Kato K, Andoh M : Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma. *Int J Clin Oncol* 25: 972-977, 2020
- Okano N, Morizane C, Nomura S, Takahashi H, Tsumura H, Satake H, Mizuno N, Tsuji K, Shioji K, Asagi A, Yasui K, Kitagawa S, Kashiwada T, Ishiguro A, Kanai M, Ueno M, Ogura T, Shimizu S, Tobimatsu K, Motoya M, Nakashima K, Ikeda M, Okusaka T, Furuse J : Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). *Int J Clin Oncol*, 25: 1835-184, 2020
- Kotaka M, Iwamoto S, Satake H, Sakai D, Kudo T, Fukunaga M, Konishi K, Ide Y, Ikumoto T, Tsuji A, Sano Y, Kato T, Sugimoto N, Satoh T, Kanazawa A, Kurata T, Yamanaka T, Tomita N : Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). *Int J Clin Oncol*, 25: 1515-1522, 2020
- Kawano F, Yonekawa T, Yamaguchi H, Shibata N, Tashiro K, Ikenoue M, Munakata S, Higuchi K, Tanaka H, Sato Y, Hosokawa A, Takeno S, Nakamura K, Nanashima A: Nasogastric administration of lenvatinib solution in a mechanically ventilated patient with rapidly

growing anaplastic thyroid cancer, *Endocrinology, Diabetes & Metabolism Case Reports*, 20-0064, 2020

Boku S, Watanabe M, Sukeno M, Yaoi T, Hirota K, Iizuka-Ohashi M, Itoh K, Sakai T:

Deactivation of Glutaminolysis Sensitizes PIK3CA-Mutated Colorectal Cancer Cells to Aspirin-Induced Growth Inhibition. *Cancers (Basel)*, 12: 1097, 2020.

柴田伸弘：連載 がん薬物専門医講座がん薬物療法専門医のための模擬テスト 125, 腫瘍内科 2020, 26(2) : 225-226.

柴田伸弘：連載 がん薬物専門医講座がん薬物療法専門医のための模擬テスト 125—解答と解説編一, 腫瘍内科 2020, 26(3) : 347-353.

佐竹悠良：『オンコロジークリニカルガイド 消化器癌化学療法 5 版』, IV 章 消化器癌化学療法の大規模臨床試験：12 大腸癌一次治療 分子標的薬同士, 265-272 頁, 南山堂, 東京, 2021

佐竹悠良：『免疫チェックポイント阻害薬 実践ガイドブック 使いこなすためのコツ!』, 3 章 副作用対策：Infusion reaction, 187-191 頁, MEDICAL VIEW, 東京, 2020

柴田伸弘：『免疫チェックポイント阻害薬 実践ガイドブック 使いこなすためのコツ!』, 副腎機能障害（がん治療医の視点から）, 155-160 頁, MEDICAL VIEW, 東京, 2020